查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1538255

心臟自主神经调节市场报告：2030 年趋势、预测与竞争分析

Cardiac Autonomic Control Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

心臟自主神经调节的趋势与预测

预计到 2030 年，全球心臟自主神经调节市场将达到 229 亿美元，2024 年至 2030 年复合年增长率为 7.1%。该市场的主要驱动因素是心血管疾病盛行率的上升、人们对心臟健康的认识不断提高以及人工智慧和基于机器学习的心臟自主调节系统的日益采用。全球心臟自主神经调节市场的未来充满希望，医院/诊所、家庭使用和研究机构市场都有机会。

心臟自主神经调节：依部位分类

包含按产品类型、应用、最终用途和地区分類的心臟自主调节的全球市场预测。

心臟自主神经调节市场洞察

Lucintel 预测，治疗领域将在预测期内经历最高的成长。

在这个市场中，医院和诊所预计将在预测期内实现最高成长。

在预测期内，北美仍将是最大的地区。

常问问题

Q1.市场规模为：

A1. 到 2030 年，全球心臟自主神经调节市场预计将达到 229 亿美元。

Q2.市场成长预测是多少：

A2. 2024 年至 2030 年，全球心臟自主神经调节市场预计将以 7.1% 的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动力是心血管疾病盛行率的上升、心臟健康意识的提高以及人工智慧和基于机器学习的心臟自主神经调节系统的日益采用。

Q4.市场的主要细分市场是：

A4. 心臟自主神经调节市场的前景广阔，在医院/诊所、家庭使用和研究机构市场都有机会。

Q5.市场的主要企业是：

A5. 涉及心臟自主神经调节的主要企业如下：

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计治疗药物将在预测期内达到最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 预计北美在预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球心臟自主神经调节市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球心臟自主神经调节市场趋势（2018-2023）与预测（2024-2030）
  • 按产品类型分類的全球心臟自主神经调节市场
    • 心率变异性 (HRV) 监测器
    • 血压计
    • 心电图监视器
    • 其他的
  • 按应用分類的全球心臟自主调节市场
    • 诊断
    • 治疗
    • 研究
  • 按最终用途分類的全球心臟自主神经调节市场
    • 医院/诊所
    • 家庭使用
    • 研究所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球心臟自主神经调节市场
  • 北美心臟自主神经调节市场
  • 欧洲心臟自主神经系统调节市场
  • 亚太心臟自主神经调节市场
  • 其他地区心臟自主神经调节市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
  • 全球心臟自主神经调节市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球心臟自主神经调节市场的产能扩张
    • 全球心臟自主神经调节市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare
简介目录

Cardiac Autonomic Control Trends and Forecast

The future of the global cardiac autonomic control market looks promising with opportunities in the hospital and clinic, home use, and research institute markets. The global cardiac autonomic control market is expected to reach an estimated $22.9 billion by 2030 with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are rising prevalence of cardiovascular diseases, increasing awareness of heart health, and expanding adoption of artificial intelligence and machine learning based cardiac autonomic control system.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cardiac Autonomic Control by Segment

The study includes a forecast for the global cardiac autonomic control by product type, application, end use, and region.

Cardiac Autonomic Control Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Heart Rate Variability (HRV) Monitors
  • Blood Pressure Monitors
  • ECG Monitors
  • Others

Cardiac Autonomic Control Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnostics
  • Therapeutics
  • Research

Cardiac Autonomic Control Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals and Clinics
  • Home Uses
  • Research Institutes
  • Others

Cardiac Autonomic Control Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cardiac Autonomic Control Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cardiac autonomic control companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cardiac autonomic control companies profiled in this report include-

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare

Cardiac Autonomic Control Market Insights

Lucintel forecasts that therapeutic is expected to witness the highest growth over the forecast period.

Within this market, hospital and clinic is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period.

Features of the Global Cardiac Autonomic Control Market

Market Size Estimates: Cardiac autonomic control market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cardiac autonomic control market size by product type, application, end use, and region in terms of value ($B).

Regional Analysis: Cardiac autonomic control market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, applications, end uses, and regions for the cardiac autonomic control market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cardiac autonomic control market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cardiac autonomic control market size?

Answer: The global cardiac autonomic control market is expected to reach an estimated $22.9 billion by 2030.

Q2. What is the growth forecast for cardiac autonomic control market?

Answer: The global cardiac autonomic control market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cardiac autonomic control market?

Answer: The major drivers for this market are rising prevalence of cardiovascular diseases, increasing awareness of heart health, and expanding adoption of artificial intelligence and machine learning based cardiac autonomic control system.

Q4. What are the major segments for cardiac autonomic control market?

Answer: The future of the cardiac autonomic control market looks promising with opportunities in the hospital and clinic, home use, and research institute markets.

Q5. Who are the key cardiac autonomic control market companies?

Answer: Some of the key cardiac autonomic control companies are as follows:

  • Medtronic
  • Abbott
  • Boston Scientific
  • Biotronik
  • MicroPort Scientific
  • LivaNova
  • Nihon Kohden
  • Schiller
  • Johnson & Johnson
  • GE Healthcare

Q6. Which cardiac autonomic control market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic is expected to witness the highest growth over the forecast period.

Q7. In cardiac autonomic control market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cardiac autonomic control market by product type (heart rate variability (HRV) monitors, blood pressure monitors, ECG monitors, and others), application (diagnostics, therapeutics, and research), end use (hospitals and clinics, home users, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cardiac Autonomic Control Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cardiac Autonomic Control Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cardiac Autonomic Control Market by Product Type
    • 3.3.1: Heart Rate Variability (HRV) Monitors
    • 3.3.2: Blood Pressure Monitors
    • 3.3.3: ECG Monitors
    • 3.3.4: Others
  • 3.4: Global Cardiac Autonomic Control Market by Application
    • 3.4.1: Diagnostics
    • 3.4.2: Therapeutics
    • 3.4.3: Research
  • 3.5: Global Cardiac Autonomic Control Market by End Use
    • 3.5.1: Hospitals and Clinics
    • 3.5.2: Home Uses
    • 3.5.3: Research Institutes
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cardiac Autonomic Control Market by Region
  • 4.2: North American Cardiac Autonomic Control Market
    • 4.2.1: North American Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.2.2: North American Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others
  • 4.3: European Cardiac Autonomic Control Market
    • 4.3.1: European Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.3.2: European Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others
  • 4.4: APAC Cardiac Autonomic Control Market
    • 4.4.1: APAC Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.4.2: APAC Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others
  • 4.5: ROW Cardiac Autonomic Control Market
    • 4.5.1: ROW Cardiac Autonomic Control Market by Application: Diagnostics, Therapeutics, and Research
    • 4.5.2: ROW Cardiac Autonomic Control Market by End Use: Hospitals and Clinics, Home Users, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cardiac Autonomic Control Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Cardiac Autonomic Control Market by Application
    • 6.1.3: Growth Opportunities for the Global Cardiac Autonomic Control Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cardiac Autonomic Control Market by Region
  • 6.2: Emerging Trends in the Global Cardiac Autonomic Control Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cardiac Autonomic Control Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cardiac Autonomic Control Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Medtronic
  • 7.2: Abbott
  • 7.3: Boston Scientific
  • 7.4: Biotronik
  • 7.5: MicroPort Scientific
  • 7.6: LivaNova
  • 7.7: Nihon Kohden
  • 7.8: Schiller
  • 7.9: Johnson & Johnson
  • 7.10: GE Healthcare